Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Invivyd, Inc. - Common Stock (NQ: IVVD )

2.295 -0.055 (-2.34%)
Streaming Delayed Price Updated: 3:26 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Invivyd, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
From Invivyd
Via GlobeNewswire
Invivyd Announces CEO Transition
Jeremy Gowler appointed Interim CEO 
From Invivyd
Via GlobeNewswire
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
From Invivyd
Via GlobeNewswire
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
From Invivyd
Via GlobeNewswire
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
From Invivyd
Via GlobeNewswire
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Invivyd
Via GlobeNewswire
Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents
From Invivyd
Via GlobeNewswire
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
From Invivyd
Via GlobeNewswire
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd to Participate in Upcoming Investor Conferences
From Invivyd
Via GlobeNewswire
Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19
Initial primary endpoint data anticipated in late 2023 or early Q1 2024 
From Invivyd
Via GlobeNewswire
Invivyd to Participate in Upcoming Investor Conferences
From Invivyd
Via GlobeNewswire
Invivyd Appoints William Duke as Chief Financial Officer
From Invivyd
Via GlobeNewswire
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Dentsply, and Invivyd on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd Announces Appointment of Sara Cotter to Board Of Directors
From Invivyd
Via GlobeNewswire
INVIVYD INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Invivyd, Inc. – IVVD, ADGI
From Kahn Swick & Foti, LLC
Via Business Wire
Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
From Invivyd
Via GlobeNewswire
INVIVYD INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Invivyd, Inc. – IVVD, ADGI
From Kahn Swick & Foti, LLC
Via Business Wire
Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19
From Invivyd
Via GlobeNewswire
Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
From Invivyd
Via GlobeNewswire
Invivyd to Participate at the Jefferies Healthcare Conference
From Invivyd
Via GlobeNewswire
INVIVYD ALERT: Bragar Eagel & Squire, P.C. is Investigating Invivyd, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
NASDAQ:IVVD Long Term Investor Alert: Investigation over Potential Wrongdoing at Invivyd, Inc.
San Diego, CA -- (SBWIRE) -- 05/25/2023 -- An investigation was announced on behalf of investors in shares of Invivyd, Inc. (NASDAQ:IVVD) over possible breaches of fiduciary duties by certain directors... 
Via SBWire
Invivyd Reports First Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd to Participate at H.C. Wainwright’s BioConnect Investor Conference
From Invivyd
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.